

Unless otherwise defined herein, capitalised terms in this announcement shall have the same meanings as those defined in the prospectus dated 29 October 2019 (the “**Prospectus**”) issued by TOT BIOPHARM International Company Limited (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering before deciding whether or not to invest in any Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories, its possessions and all areas subject to its jurisdiction). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or any other jurisdictions. The Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to registration or an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offer of securities in the United States.

东曜药业

TOT BIOPHARM International Company Limited

東曜藥業股份有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1875)

STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF THE OVER-ALLOTMENT OPTION

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on 1 December 2019, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Further information of the stabilizing actions undertaken during the stabilization period by ICBC International Securities Limited, as the stabilizing manager (the “**Stabilizing Manager**”), or any person acting for it is set out in this announcement.

LAPSE OF THE OVER-ALLOTMENT OPTION

ICBC International Capital Limited, on behalf of the International Underwriters (“**ICBCI Capital**”), did not exercise the Over-Allotment Option during the stabilization period, and the Over-Allotment Option lapsed on 1 December 2019.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on 1 December 2019, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. The stabilizing actions undertaken during the stabilization period by the Stabilizing Manager or any person acting for it were:

- (1) the over-allocations of an aggregate of 5,000,000 Shares in the International Offering, representing approximately 5.56% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-Allotment Option);
- (2) the borrowing of 5,000,000 Shares by the Stabilizing Manager from Centerlab pursuant to a stock borrowing agreement dated 1 November 2019 to cover over-allocations of Shares in the International Offering. Such Shares will be returned and redelivered to Centerlab in accordance with the terms of such stock borrowing agreement; and
- (3) the successive purchases of an aggregate of 5,000,000 Shares at the price range of HK\$4.90 to HK\$6.43 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) on the market during the stabilization period. The last purchase made by the Stabilizing Manager on the market during the stabilization period was on 29 November 2019 at the price of HK\$5.13 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%).

LAPSE OF THE OVER-ALLOTMENT OPTION

ICBCI Capital did not exercise the Over-Allotment Option during the stabilization period, and the Over-Allotment Option lapsed on 1 December 2019.

PUBLIC FLOAT

The Company continues to comply with the public float requirements under Rule 8.08(1)(a) and Rule 18A.07 of the Listing Rules that at least 25% of the Company's total issued share capital with a market capitalization of at least HK\$375 million must at all times be held by the public.

By order of the Board
TOT BIOPHARM International Company Limited
Yeh-Huang, Chun-Ying
Executive Director

Hong Kong, 2 December 2019

As at the date of this announcement, the executive Directors are Ms. Yeh-Huang, Chun-Ying and Dr. Liu, Jun; the non-executive Directors are Mr. Fu, Shan, Dr. Kung, Frank Fang-Chien, Mr. Kang, Pei and Mr. Qiu, Yu Min; and the independent non-executive Directors are Ms. Hu, Lan, Dr. Sun, Lijun Richard and Mr. Chang, Hong-Jen.